Visualitza per autor "Manso, Luis"
Ara mostrant els elements 1-5 d 5
-
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
Quintela-Fandino, Miguel; Holgado, Esther; Manso, Luis; Bermejo, Begoña; Colomer, Ramon; Cortés Castan, Javier; Morales, Serafin (BMC, 2020-11-11) -
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
Gil-Gil, Miguel J.; Bergamino, Milana; Barnadas, Agustí; Manso, Luis; Bellet Ezquerra, Meritxell; Saura Manich, Cristina; Morales, Serafin (Frontiers Media, 2021-07) -
Management of advanced ovarian cancer in Spain: an expert Delphi consensus
Redondo Sanchez, Andres; Oaknin Benzaquen, Ana Mazaltob; Rubio, Maria Jesus; Barretina-Ginesta, Maria-Pilar; de Juan Ferre, Ana; Manso, Luis (BMC, 2021-05-26) -
Palbociclib combined with endocrine therapy in heavily pretreated HR + /HER2 - advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)
Manso, Luis; Hernando, Cristina; Antunes de Melo Oliveira, Ana Mafalda; Cabrera, Miguel A.; Bratos, Raquel; Galán, María (Elsevier, 2020-12-01) -
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A
Mouron, Silvana; Bueno, MJ; Lluch, Ana; Manso, Luis; Calvo, Isabel; Cortés Castan, Javier (Springer Nature, 2022-12-07)